Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion>. }
Showing items 1 to 9 of
9
with 100 items per page.
- association type Statement assertion.
- association label ""* Active pathological bleeding ( 4.1 4.2 4.3 Prasugrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions ( 5.1 6.1 Prasugrel tablets is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. In TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Prasugrel tablets (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). In patients without such a history, the incidence of stroke was 0.9% (0.2% ICH) and 1.0% (0.3% ICH) with Prasugrel tablets and clopidogrel, respectively. Patients with a history of ischemic stroke within 3 months of screening and patients with a history of hemorrhagic stroke at any time were excluded from TRITON-TIMI 38. Patients who experience a stroke or TIA while on Prasugrel tablets generally should have therapy discontinued [see Adverse Reactions ( 6.1 14 Prasugrel tablets is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to prasugrel or any component of the product [see Adverse Reactions ( 6.2"" assertion.
- association subject drugbank:DB06209 assertion.
- association predicate treats assertion.
- association object DOID_224 assertion.
- association relation MedicalContraindication assertion.
- drugbank:DB06209 category Drug assertion.
- DOID_224 category Disease assertion.
- association provided_by NeuroDKG assertion.